论文部分内容阅读
目的评价口服依托泊苷治疗转移性乳腺癌的疗效和不良反应。方法回顾性分析88例接受口服依托泊苷治疗的转移性乳腺癌患者资料。口服依托泊苷50 mg/d,d1~20,每28天为一周期。结果共纳入88例乳腺癌患者,83.0%(73/88)为三线以上治疗,78.4%(69/88)既往用蒽环类、紫杉类药物及卡培他滨治疗过。88例患者采用口服依托泊苷方案中位化疗5周期,均可评价疗效,其中部分缓解(PR)7例(8.0%),疾病稳定(SD)50例(56.8%),疾病进展(PD)31例(35.2%),无完全缓解(CR)患者。客观缓解率(CR+PR)为8.0%,临床获益率(CR+PR+SD≥6.0月)为44.3%。整体中位无进展生存期(PFS)为5.0月(95%CI:3.8~6.2月),中位生存期(OS)为17.0月(95%CI:11.3~22.7月)。主要不良反应为1~2级恶心18例(20.5%),1~2级中性粒细胞减少19例(21.6%),3级中性粒细胞减少3例(3.4%)。结论口服依托泊苷治疗难治性转移性乳腺癌耐受性好、有一定疗效。
Objective To evaluate the efficacy and adverse reactions of oral etoposide in the treatment of metastatic breast cancer. Methods A retrospective analysis of 88 patients receiving oral etoposide treatment of metastatic breast cancer patients. Etoposide oral 50 mg / d, d1 ~ 20, every 28 days for a cycle. Results A total of 88 patients with breast cancer were enrolled, with 83.0% (73/88) being treated for more than three lines and 78.4% (69/88) previously treated with anthracyclines, taxanes and capecitabine. Eighty-eight patients underwent oral etoposide for 5 cycles of chemotherapy, including partial response (8.0%), stable disease (SD), 50 cases (56.8%), disease progression (PD) 31 cases (35.2%), no complete remission (CR) patients. The objective response rate (CR + PR) was 8.0%, and the clinical benefit rate (CR + PR + SD≥6.0) was 44.3%. The overall median progression-free survival (PFS) was 5.0 (95% CI: 3.8-8.2 months) and the median OS was 17.0 (95% CI: 11.3-22.7). The main adverse reactions were grade 1 to grade 2 nausea in 18 (20.5%), grade 1 to 2 neutropenia in 19 (21.6%) and grade 3 neutropenia in 3 (3.4%). Conclusion Oral etoposide treatment of refractory metastatic breast cancer is well tolerated and has a certain effect.